Researchers have developed a groundbreaking way to engineer yeast (Saccharomyces cerevisiae) to create microbial communities that can perform complex tasks and self-regulate their composition in ...
On Thursday, the FDA granted full approval to Humacyte, Inc.’s (NASDAQ:HUMA) Symvess (acellular tissue-engineered vessel-tyod) use in adults as a vascular conduit for extremity arterial injury when ...
When biomedical researchers need to test their latest ideas, they often turn to engineered human tissue that mimics the ...
An investigational product called Acellular Tissue Engineered Vessel demonstrated superior hemodialysis vascular access outcomes compared with AVFs in a phase 3 trial. A bioengineered human tissue ...
The Mayo Foundation for Medical Education and Research, the nonprofit parent entity of the Mayo Clinic, is a worldwide research powerhouse that is assigned scores of U.S. patents each year. Mayo ...
The FDA granted a Priority Review in February 2024 and was assigned a PDUFA date of August 10, 2024. ATEV is a bioengineered human tissue designed to be a universally implantable vascular conduit for ...
The FDA on Friday approved acellular tissue engineered vessel (Symvess), an off-the-shelf product for treating vascular trauma in the extremities of adults. The one-time, single-use therapy -- the ...
The Grande Ronde Hospital (GRH) Wound Clinic, located at 700 Sunset Dr., Suite F, has experienced significant growth over the past 15 years, evolving from a single-room clinic in the SurgiCenter that ...
Intermountain Medical Center participated in a trial of the first bioengineered external liver, designed to help acute liver failure patients or are not eligible for or are waiting for a transplant a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback